US Pharma MarketingOtsuka reports long-term kidney data key to Voyxact
The data are crucial to Otsuka’s bid to get a full approval for Voyxact, as rival Vera Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug…
Otsuka on Thursday reported new long-term data that it hopes will convert an accelerated approval to a full green light in kidney disease.
The company said the Phase 3 study showed Voyxact stabilized kidney function ...
Source: Endpoints News